Hayflick 1961 50-doubling limit; Harley-Greider-Blackburn telomere-shortening 1990 (Nobel 2009); SASP senescence-associated secretory phenotype; senolytic drugs Phase 2 2024.
Hayflick 1961 50-doubling limit; Harley-Greider-Blackburn telomere-shortening 1990 (Nobel 2009); SASP senescence-associated secretory phenotype; senolytic drugs Phase 2 2024.